Total item
Cart Subtotal
$0.00 TAM Receptor
| Catalog No. | Inhibitor Name | Mer | Axl | Tyro3 | Other |
|---|---|---|---|---|---|
| A10996 | Cabozantinib | *** | |||
| A10153 | BMS-777607 | ** | **** | **** | VEGFR2/KDR,c-Met,Kit |
| A13741 | R428 | ** | RON,Met,FLT3 | ||
| A14143 | UNC2250 | **** | * | VEGFR2/KDR,c-Met,Kit | |
| A15904 | UNC2025 | **** | ** | ** | |
| A15776 | TP-0903 | ** | FLT3 | ||
| A15917 | NPS-1034 | *** | |||
| A13003 | LDC1267 | *** | * | *** | Met |
| A14276 | UNC2881 | **** | * | * |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
16 Item(s)
per page
-
XL184 free base (Cabozantinib)
Catalog No. A10996 VEGFR inhibitorXL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. Learn More -
BMS-777607
Catalog No. A10153 c-Met inhibitorBMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway. Learn More -
R428
Catalog No. A13741 Axl InhibitorR428 is a selective small molecule inhibitor of Axl kinase, which showed activity to blocks tumor spread and prolongs survival in models of metastatic breast cancer. Learn More -
Gilteritinib (ASP2215)
Catalog No. A14411 FLT3/Axl inhibitorGilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. Learn More -
TP-0903
Catalog No. A15776 AXL InhibitorTP-0903 is a potent and selective Axl kinase inhibitor with IC50 of 27 nM. Learn More -
SGI-7079
Catalog No. A15864 Axl inhibitorSGI-7079 ,a novel selective Axl inhibitor, inhibits tumor growth in a dose dependent manner and is a potential therapeutic target for overcoming EGFR inhibitor resistance. Learn More -
Glesatinib hydrochloride
Catalog No. A16257 MET/Axl inhibitorGlesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. Learn More -
UNC 2250
Catalog No. A14143 Selective Mer Kinase inhibitorUNC2250 is a potent and selective Mer Kinase inhibitor. Learn More -
UNC2881
Catalog No. A14276 Mer tyrosine kinase inhibitorUNC2881 is a specific Mer tyrosine kinase inhibitor Learn More -
UNC569
Catalog No. A13805 Mer InhibitorUNC569 is a novel small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. UNC569 is the first small-molecule Mer inhibitor. UNC569 inhibited Mer activation and downstream signaling through ERK1/2 and AKT. Learn More -
LDC1267
Catalog No. A13003 TAM Receptor inhibitorLDC1267 is a highly selective TAM(Tyro3, Axl and Mer) kinase inhibitor with IC50 of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively. Learn More -
NPS-1034
Catalog No. A15917 c-Met inhibitorNPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively. Learn More -
R916562
Catalog No. A19374 Axl/VEGFR2 inhibitorR916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis. Learn More -
Gilteritinib hemifumarate
Catalog No. A18235 FLT3/AXL inhibitorGilteritinib hemifumarate is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. Learn More -
S49076
Catalog No. A21407 MET, AXL/MER, and FGFR1/2/3 inhibitorS49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. Learn More -
BMS 777607
Catalog No. A21638 c-Met/Axl/Ron/Tyro3 inhibitorBMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. Learn More
16 Item(s)
per page
Adooq Quality Guarantee
We promise all products perform as described.